Sublime China Information (301299.SZ) submitted an application for the issuance and listing of H shares to the Hong Kong Stock Exchange and published the application materials.

16:24 30/11/2025

Zhuochuang Information (301299.SZ) announced that the company has submitted an application to the Stock Exchange of Hong Kong on November 28, 2025 to issue overseas listed shares (H shares) and list on the Main Board of the Stock Exchange of Hong Kong. The application materials have been published on the Stock Exchange of Hong Kong website on the same day. The application materials are prepared and published by the company in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Stock Exchange of Hong Kong. They are draft versions, and the information contained in them may be updated and revised in due course.

Sublime China Information (301299.SZ) announced that the company has submitted an application for the issuance of overseas listed shares (H shares) to the Hong Kong Stock Exchange on November 28, 2025 and has applied for listing on the main board of the Hong Kong Stock Exchange. On the same day, the application materials for this issuance and listing were posted on the Hong Kong Stock Exchange website. The application materials were prepared and published by the company in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, and are draft versions. The information contained in the materials may be updated and revised in due course.

China Shenhua Energy (601088.SH): The No. 3 unit of the Beihai Phase II has passed the 168-hour trial run.

Subsidiary of Sichuan Biokin Pharmaceutical (688506.SH) receives milestone payment of $250 million from Roche for the Iza-Bren project.

Wus Printed Circuit (002463.SZ) submitted an application for listing H-shares on the Hong Kong Stock Exchange and published the application materials.

China Shenhua Energy (601088.SH): The No. 3 unit of the Beihai Phase II has passed the 168-hour trial run.

Subsidiary of Sichuan Biokin Pharmaceutical (688506.SH) receives milestone payment of $250 million from Roche for the Iza-Bren project.

Wus Printed Circuit (002463.SZ) submitted an application for listing H-shares on the Hong Kong Stock Exchange and published the application materials.